uniQure (QURE) Reports Q2 Loss of EUR0.51/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- S&P Global explores potential separation of Capital IQ business
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
uniQure Announces Financial Results for Second Quarter 2015
August 27, 2015 5:06 AM EDTAMSTERDAM, the Netherlands, Aug. 27, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the second quarter and six months ending June 30, 2015, and provided an update on multiple gene therapy programs.
"We are very pleased with the significant progress uniQure has made during the first half of 2015 and believe that uniQure is in a strong position to achieve its goal of delivering on the promise of gene therapy to patients," said Jörn Aldag, uniQure Chief Executive Officer. "The closing of our strategic collaboration with... More



